CINECA IRIS Institutional Research Information System

LEONE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.464
EU - Europa 3.369
AS - Asia 2.840
SA - Sud America 100
OC - Oceania 72
AF - Africa 31
Continente sconosciuto - Info sul continente non disponibili 12
Totale 11.888
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.318
CN - Cina 1.778
IT - Italia 839
DE - Germania 447
JP - Giappone 336
FR - Francia 328
GB - Regno Unito 306
IE - Irlanda 274
ES - Italia 227
SE - Svezia 212
KR - Corea 131
IN - India 124
FI - Finlandia 120
CA - Canada 117
UA - Ucraina 116
VN - Vietnam 89
PL - Polonia 73
BR - Brasile 71
TW - Taiwan 71
TR - Turchia 70
CH - Svizzera 65
NL - Olanda 58
BE - Belgio 57
AU - Australia 55
HK - Hong Kong 54
GR - Grecia 51
RU - Federazione Russa 45
SG - Singapore 44
TH - Thailandia 33
MX - Messico 26
RO - Romania 25
SA - Arabia Saudita 23
AT - Austria 21
PT - Portogallo 20
DK - Danimarca 18
IR - Iran 18
NZ - Nuova Zelanda 17
EG - Egitto 14
CZ - Repubblica Ceca 13
HU - Ungheria 13
IL - Israele 13
ID - Indonesia 11
MY - Malesia 11
CL - Cile 10
EU - Europa 9
PK - Pakistan 9
HR - Croazia 8
AR - Argentina 7
LB - Libano 6
KE - Kenya 5
PE - Perù 5
PH - Filippine 5
SI - Slovenia 5
CO - Colombia 4
EE - Estonia 4
LU - Lussemburgo 4
NO - Norvegia 4
OM - Oman 4
ZA - Sudafrica 4
AP - ???statistics.table.value.countryCode.AP??? 3
IS - Islanda 3
JO - Giordania 3
MK - Macedonia 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
BG - Bulgaria 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
QA - Qatar 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
BT - Bhutan 1
EC - Ecuador 1
ET - Etiopia 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MU - Mauritius 1
NG - Nigeria 1
PA - Panama 1
PY - Paraguay 1
RS - Serbia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 11.888
Salva come PNG Salva come JPEG
Città #
Beijing 518
Chandler 473
Fairfield 384
Houston 335
Dublin 271
Shanghai 263
Ashburn 227
Woodbridge 208
Wilmington 203
Seattle 195
Ann Arbor 193
Redwood City 164
Torino 150
Cambridge 145
Dearborn 125
Villeurbanne 125
Nyköping 113
Guangzhou 109
Jacksonville 105
Pisa 102
Tokyo 98
Princeton 94
Medford 84
Nanjing 75
Milan 68
Warsaw 64
New York 62
Dong Ket 55
Zhengzhou 54
Boston 53
Chengdu 46
Hangzhou 44
Wuhan 43
Duncan 41
Taipei 41
San Diego 39
Munich 38
Rome 36
Jinan 35
Hefei 34
Madrid 33
Istanbul 31
Paris 31
Barcelona 30
London 30
Brussels 29
Singapore 29
Toronto 27
Norwalk 26
Los Angeles 25
Seoul 25
Boardman 24
Chicago 24
Turin 23
Ottawa 22
Tianjin 22
Shenyang 21
Aioicho 19
Berlin 19
Salt Lake City 19
Fremont 18
Phoenix 18
Amsterdam 17
Philadelphia 17
Chongqing 15
Hebei 15
San Francisco 15
Shenzhen 15
Dallas 14
Montreal 14
Silver Spring 14
Athens 13
Atlanta 13
Changsha 13
Nutley 13
Helsinki 12
Newbury Park 12
Pune 12
Rochester 12
San Mateo 12
São Paulo 12
Verona 12
Washington 12
Bangkok 11
Columbus 11
Manchester 11
Vancouver 11
Nanchang 10
Riyadh 10
Sydney 10
Auckland 9
Central District 9
Charlotte 9
Florence 9
Osaka 9
Upper Marlboro 9
Utrecht 9
Central 8
Cleveland 8
Columbia 8
Totale 6.502
Salva come PNG Salva come JPEG
Nome #
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 4.825
Emerging molecular target antagonists for the treatment of biliary tract cancer 652
A phase I dose-escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. 425
Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy. 242
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study) 230
Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy 206
Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18 F-FDG PET and MRI radiomics features 162
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor 147
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 145
The Role of Lung Metastasis Resection in Improving Outcome of Colorectal Cancer Patients: Results from a Large Retrospective Study. 141
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma 138
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 136
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. 135
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 132
Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR 119
Fluoropyrimidine-induced cardiotoxicity 118
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: A case report 116
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. 115
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives 114
Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line 113
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 113
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: A multicenter survey and pooled analysis with published data 112
The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005 104
Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine 104
PHASE II TRIAL OF PANITUMUMAB IN COMBINATION WITH OXALIPLATIN AND CAPECITABINE CHEMOTHERAPY AS 1ST LINE THERAPY IN PATIENTS WITH COLORECTAL CANCER AND ADVANCED LIVER METASTASES: THE METAPAN STUDY 103
Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients 102
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas 101
Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab 92
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 92
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 92
Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? 89
Bone metastases in biliary cancers: A multicenter retrospective survey 87
High prevalence of hepatitis C virus (HCV) genotype 2 in Italian patients with chronic liver disease. 84
Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives 82
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases: The MetaPan study. 81
Antitumor activity of Src inhibitor Saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. 78
[Diagnosis of neoplastic ascites: combined use of albumin gradient between serum and ascites and cholesterol in ascitic fluid] 73
Epidemiological and virological analysis of couples infected with hepatitis C virus. 72
Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. 72
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient 70
Rationale for the use of metronomic chemotherapy in gastrointestinal cancer 69
Diagnostic paracentesis. A two-step approach. 68
GAS6, the ligand of Axl and Rse receptors, is expressed in hematopoietic tissue but lacks mitogenic activity. 68
Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction. 66
Biliary tract carcinomas: From chemotherapy to targeted therapy. 63
LONG-TERM SURVIVAL OF PATIENTS WITH RESECTION OF PULMONARY METASTASES FROM COLORECTAL NEOPLASMS AS COMPARED TO NOT RESECTED ONES. A RETROSPECTIVE STUDY ON PATIENTS FOLLOWED FROM THE TIME OF FIRST RECURRENCE 62
Assessment of a HER2 scoring system for colorectal cancer: Results from a validation study 61
Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors 60
Evaluation of iron status in patients with chronic hepatitis C. 58
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 56
Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy 52
Capecitabine with/without mitomycin C: Results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma 51
Adjuvant chemotherapy and follow-up 49
Linifanib: Current status and future potential in cancer therapy 49
A novel multidrug‐resistant cell line from an italian intrahepatic cholangiocarcinoma patient 49
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 48
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 48
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 47
Phlebotomy reduces serum procollagen III peptide levels in patients with chronic hepatitis C. 46
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 45
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 45
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study 44
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 43
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 43
Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients 42
Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. 41
Targeted agents: how can we improve the outcome in biliary tract cancer? 41
Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach 41
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 41
“Shades of Gray” in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer 41
Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection. 39
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. 37
Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. 37
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 37
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 36
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 35
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 35
Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: A single institutional experience. 33
Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma 33
Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma 32
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 32
Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience 30
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 30
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 24
Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT) 17
Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience 13
Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy 2
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 2
Totale 12.255
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.346
article - articoli 0
book - libri 0
conference - conferenze 391
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.737
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019405 0 0 0 0 0 0 0 0 0 0 266 139
2019/20202.228 138 128 147 268 195 282 200 198 213 192 153 114
2020/20211.620 111 126 146 136 138 101 137 99 166 138 131 191
2021/20221.652 130 138 96 108 130 95 133 145 90 92 286 209
2022/20231.882 191 173 71 171 155 341 146 125 197 90 137 85
2023/20241.147 143 176 109 113 115 145 101 117 28 91 9 0
Totale 12.255